Literature review · Muscle & strength

Sermorelin

Human research includes route-specific GH-response experiments and a small uncontrolled functional study in older men. Limited positive strength measures did not establish a reliable performance benefit.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Selected evidence includes human route-specific pharmacokinetics and a small uncontrolled study that measured strength, muscle bioenergetics and body composition in older men.

Identity & scope

The paper identifies GHRH(1-29)-NH2, the peptide commonly called sermorelin. Matching that molecular description still does not authenticate a commercial batch.

Catalogue labels covered: Sermorelin.

What the research shows

  • The same compound had route-dependent exposure in the research preparation. Total labelled milligrams cannot establish equivalent systemic exposure across formats.

Critical interpretation

One of the selected studies did measure function

The older-men study is relevant because it measured strength and muscle-related outcomes rather than hormones alone. Two of six strength measures and an endurance test improved, while body composition, muscle histology and several other measures did not. The small before-and-after design has no parallel placebo comparison in the reported experiment. Familiarity with testing, ordinary variation and multiple outcome testing therefore limit attribution of the positive measures to GHRH itself. The findings are hypothesis-generating, not a robust estimate of a strength benefit. [2]

The delivery comparison does not validate a present-day spray

The healthy-men pharmacokinetic study directly compared intravenous and intranasal GHRH(1-29)-NH2 and found low nasal bioavailability for its formulation. That establishes why molecular identity and route must be considered together. It does not mean every nasal preparation has that same exposure, or that matching the peptide name establishes equivalent delivery. A clinically useful conclusion would require both an exposure link for the actual formulation and an outcome study suited to the proposed application. [1]

Limitations & uncertainties

  • The functional study was small, uncontrolled and assessed multiple outcomes; it cannot provide a robust causal strength estimate.
  • The route study involved a specific formulation. Neither paper authenticates a catalogue material or establishes equivalent delivery.

Open research questions

  • Does the material documentation specify GHRH(1-29)-NH2 and the complete formulation?
  • Has exposure been measured for the actual formulation under investigation?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration (opens in a new tab)

Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. (1993). Acta Paediatrica Supplement. DOI: 10.1111/j.1651-2227.1993.tb12827.x (opens in a new tab) · PMID 8329825

Design & population
Intravenous and intranasal GHRH(1-29)-NH2 pharmacology experiments in 30 healthy men.
What the study found
GH responses were observed with both studied routes, while measured nasal bioavailability was low in that formulation.
Limits on interpretation
The study measured pharmacokinetics and endocrine responses. It did not establish performance benefits or equivalence to a current supplier spray.
Human studyNamed compoundAbstract / record checked

2. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (opens in a new tab)

Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997). Metabolism. DOI: 10.1016/s0026-0495(97)90174-8 (opens in a new tab) · PMID 9005976

Design & population
Six-week before-and-after study in 11 healthy older men with low baseline IGF-I, measuring hormones, several strength tests, muscle bioenergetics and body composition.
What the study found
Two of six strength measures and one endurance measure improved. Body composition, muscle histology and the measured muscle-energy responses did not change; IGF-I did not increase.
Limits on interpretation
Small uncontrolled study with multiple outcomes. Practice effects, variation and changes unrelated to treatment cannot be separated confidently from a treatment effect.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • 8329825 GHRH pharmacokinetics
  • site.pubmed.ncbi.nlm.nih.gov sermorelin GHRH 1-29 elderly physical performance randomized
  • "9005976" authors DOI

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Sermorelin: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/sermorelin.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes